Introduction {#S1}
============

In recent years, accumulating researches have shed light on the dissemination of carbapenem-resistant *Escherichia coli (E. coli)* (CR-EC) worldwide, mainly due to the acquisition of carbapenemase-related genes located on several mobile resistance elements ([@B13]; [@B5]; [@B8]).

Among the major geographically widespread carbapenemases, *bla*~NDM~ has gained further worldwide attention for its high-level resistance to many clinically available β-lactams and the incredible horizontal transfer between different isolates. Since the first report of NDM-positive isolate in 2008 ([@B25]), 24 variants of NDM enzymes have been identified to date ([@B23]). NDM-5, which differed from NDM-1 by increased carbapenemase activity and substitutions at positions 88 (Val→Leu) and 154 (Met→Leu), was first identified in a CR-EC strain in United Kingdom ([@B10]).

Notably, one of the major reasons for the rapid emergence and spread of NDM-5 is its location on different incompatibility typing plasmids ([@B6]; [@B22]). Various plasmid incompatibility typing groups carrying *bla*~NDM--5~ have been reported worldwide with the most prevalent being IncFIA/B and IncX3 in Korea ([@B2]), IncFIA and IncFIB in Egypt ([@B7]), IncFIA and IncFK in India ([@B1]), and IncFII in the United States ([@B19]). Previous studies in China have shown several sporadic cases of clinical infections linked to ST167-type *E. coli* carrying the *bla*~NDM--5~ gene, which was mainly located on the IncX3 plasmid ([@B4]; [@B24]; [@B16]; [@B20]). Unexpectedly, our initial study revealed that the epidemic incompatibility type of NDM-5 plasmid in our region is IncF, representing a new potential threat of carbapenem resistance *Enterobacteriaceae* (CRE) in China.

More importantly, the coproduction of NDM-5 and other carbapenemases in a single isolate is worthy of special concern, since it has been demonstrated to confer a higher-level resistance to carbapenems ([@B7]; [@B19]). To the best of our knowledge, this is the first report of clinical *E. coli* strains simultaneously producing NDM-5 and KPC-2 carbapenemases.

Therefore, the present study was initiated: (i) to describe the prevalence of clinical CR-EC isolates collected successively for approximately 5 years, (ii) to identify the resistance mechanisms among these CR-EC strains, and (iii) to explore the genetic context of *bla*~NDM--5~ to further elucidate the mechanisms involved in antibiotic resistance gene transferring.

Materials and Methods {#S2}
=====================

Bacterial Strains {#S2.SS1}
-----------------

This retrospective study was performed in the First Affiliated Hospital of Chongqing Medical University and associated two branch hospitals in Southwestern China. 109 non-repetitive nosocomial CR-EC strains were collected between 2013 and 2017. All the isolates were identified at the species level by the VITEK MS (bioMérieux, Hazelwood, MO, United States) automated system, and routine antimicrobial susceptibility testing was performed by using the VITEK2 compact (bioMérieux, Inc., Durham, NC, United States) system. According to the breakpoint recommendations by the Clinical and Laboratory Standards Institute, 2017 (CLSI-2017), isolates which were non-susceptible to at least one of the carbapenems by the broth microdilution method, with the criteria of minimum inhibitory concentration (MIC) of ≥2 μg/mL for ertapenem (ETP), ≥4 μg/mL for imipenem (IPM), or ≥4 μg/mL for meropenem (MEM), were included in the study.

Antibiotics and *in vitro* Susceptibility Testing {#S2.SS2}
-------------------------------------------------

All the isolates were tested for antibiotic susceptibilities to ceftazidime (CAZ), ceftriaxone (CRO), cefepime (FEP), gentamicin (GM), tobramycin (TOB), ciprofloxacin (CIP), and levofloxacin (LEV) by using AST GN13 cards on the VITEK2 compact system. MICs for ETP, IPM, MEM, colistin (CS), Aztreonam (ATM), and tigecycline (TGC) were determined using the broth microdilution method. MIC results were interpreted according to CLSI-2017 breakpoint recommendations. Non-carbapenemase-producing *E. coli* strain ATCC 25922 was served as a quality-control strain.

DNA Amplification and Analysis {#S2.SS3}
------------------------------

Total DNA was extracted by boiling centrifugation method ([@B9]). Briefly, single colonies were picked from overnight culture of each *E. coli* isolate, resuspended in 200 μl of sterile distilled water, and boiled at 100°C for 10 min. After centrifugation at 15,000 × *g* for 15 min, supernatants were collected and stored at −20 C ([@B18]). The potential presence of carbapenemase genes, including *bla*~KPC~, *bla*~NDM~, *bla*~VIM~, *bla*~IMP~, *bla*~OXA--23~, *bla*~OXA--24~, and *bla*~OXA--48~, were detected by polymerase chain reaction (PCR),and all the variants of these carbapenemase genes were confirmed by sequencing ([@B22]). Furthermore, ESBL genes, such as *bla*~CTXM~, *bla*~TME~, *bla*~SHV~, and *bla*~OXA--1~, AmpC genes, such as *bla*~ACC~, *bla*~FOX~, *bla*~MOX~, *bla*~DHA~, *bla*~CIT~, and *bla*~EBC~, porin genes, such as *ompF* and *ompC* were also determined by using primers as described previously ([Supplementary Table S1](#TS1){ref-type="supplementary-material"}). All the amplified PCR products were gel purified and sequenced by the Sanger method, while the plasmids were sequenced by the next-generation high throughput sequencing on the Illumina Hiseq 2000 (Illumina Inc., San Diego, CA, United States) platform.

Conjugation, Transformation, and Plasmid Analysis {#S2.SS4}
-------------------------------------------------

To assess whether the carbapenemase-producing genes were located on the plasmids, conjugation with *E. coli* EC600 and transformation with *E. coli* DH5α were repeatedly conducted. For conjugative assays, the rifampin-resistant *E. coli* EC600 strain was use as the recipient, and the transconjugants were selected on Mueller-Hinton agar plates supplemented with a combination of 32 μg/ml ampicillin and 512 μg/ml rifampin. For transformation assays, the transformants were selected on Mueller-Hinton agar plates containing 2 μg/ml MEM ([@B14]). Both the transconjugants and transformants were tested for antimicrobial susceptibilities by the VITEK2 compact system, and MICs for ETP, IPM, MEM, colistin (CS), and tigecycline (TGC) were further determined by the broth microdilution method. The presence of resistance determinants were confirmed by PCR.

Plasmids carrying *bla*~NDM~ were extracted from transconjugants using a QIAGEN Plasmid Mini Kit (QIAGEN, Germany) according to the manufacturer's instructions. To investigate the genetic context around the *bla*~NDM--5~ gene, we first chose the plasmid pNDM5-1001 which was extracted from transconjugant and harbored a *bla*~NDM--5~ gene for sequencing. The whole plasmid sequence was obtained on the HiSeq 2000 platform (Illumina Inc., San Diego, CA, United States) generating 400 bp paired-end reads. Then, the derived reads were trimmed and assembled using SOAP *de novo* v2.04^[1](#footnote1){ref-type="fn"}^, and gaps were closed through PCR and Sanger sequencing. Sequence analysis was done by both the ORF Finder^[2](#footnote2){ref-type="fn"}^ and the BLAST functions^[3](#footnote3){ref-type="fn"}^. The genomes of the plasmids were annotated by GeneMarkS^[4](#footnote4){ref-type="fn"}^. The circular map of the pNDM5-1001 plasmid was generated using the Snap Gene server^[5](#footnote5){ref-type="fn"}^.

A comparison of pNDM5-1001 and four other related plasmids pGUE_NDM (accession number [JQ364967.1](JQ364967.1)), pNDM5-020007 (accession number [CP025626.1](CP025626.1)), pNDM-5-IT (accession number [MG649062.1](MG649062.1)), and pNDM-BJ01 (accession number [JQ001791.1](JQ001791.1)) was performed with Mauve^[6](#footnote6){ref-type="fn"}^.

Incompatibility typing of the *bla*~NDM~ plasmid was performed by PCR-based replicon typing ([@B3]).

Genetic Environments of *bla*~NDM~-Carrying Plasmids {#S2.SS5}
----------------------------------------------------

The genetic environment of *bla*~NDM~ was established by PCR as described previously ([@B26]). Primers were designed based on the reported *bla*~NDM~ flanking sequences to determine the genetic background of the *bla*~NDM~-harboring strains ([Supplementary Tables S2](#TS2){ref-type="supplementary-material"}, [S3](#TS3){ref-type="supplementary-material"}). PCR experiments were performed using the same thermocycling conditions for all strains as follows: one cycle of 94°C for 5 min; followed by 35 cycles of 94°C for 35 s, 56°C for 45 s, and 72°C for 1 min; and a final cycle at 72°C for 10 min. The amplified products were sequenced and compared with the similar sequences deposited in the BLAST database, and the DNA sequences obtained were compared with those available in the NCBI GenBank database.

Multi-Locus Sequence Typing (MLST) and Pulsed-Field Gel Electrophoresis (PFGE) {#S2.SS6}
------------------------------------------------------------------------------

Multi-locus sequence typing (MLST) was performed by the amplifications of the internal fragments of seven housekeeping genes of carbapenemase-producing *E. coli* isolates (*adk*, *fumC*, *icd*, *purA*, *gyrB*, *recA*, and *mdh*) according to the database^[7](#footnote7){ref-type="fn"}^. The clonal relationships of the isolates harboring the *bla*~NDM--5~ gene were further determined by pulsed-field gel electrophoresis (PFGE). Briefly, genomic DNA of the *bla*~NDM--5~-positive *E. coli* isolates was prepared in agarose blocks and digested with restriction enzyme *Xba*I. DNA fragments were separated using a CHEF II D-Mapper XA PFGE system (Bio-Rad, Hercules, California, CA, United States) with running conditions as described previously ([@B12]).

Ethical Considerations {#S2.SS7}
----------------------

The data and samples analyzed in the present study were obtained in accordance with the standards and approved by the Chongqing Medical University Institutional Review Board and Biomedical Ethics Committee. For this study, samples were collected at the microbiology laboratory of our hospital, with no contact with the patients. This study was retrospective and there was no patient identification performed during data collection. Therefore, the ethics committee determined that informed consent was not required.

Statistical Analysis {#S2.SS8}
--------------------

All analyses were performed using SPSS v.25.0 software (SPSS Inc., Chicago, IL, United States). Univariate analyses were performed separately for each of the variables. All variables with a *P* value of ≤0.05 in the univariate analyses were considered for inclusion in the multivariate logistic regression model. The odds ratio (OR) and 95% confidence interval (CI) were calculated to evaluate the strength of any association. Categorical variables were calculated using a chi-square test or Fisher's exact test as appropriate. Continuous variables were calculated using Student *t* test (normally distributed variables) and Wilcoxon rank-sum test (non-normally distributed variables) as appropriate. For all calculations, statistical significance was defined at *P* \< 0.05 for 2-tailed tests.

Results {#S3}
=======

General Characteristics and Antimicrobial Susceptibility of CR-EC Isolates {#S3.SS1}
--------------------------------------------------------------------------

As shown in [Table 1](#T1){ref-type="table"}, a total of 109 non-repetitive CR-EC strains were isolated from 2013 to 2017 in our hospitals. These non-duplicated isolates were mainly isolated from urine, followed by the respiratory tract samples, drainage, secretion, blood, and other sources including bile and ascites. For the antimicrobial susceptibility of these isolates, our study showed the highest non-susceptible rate to ETP (97.3%), with 57.8% and 55.9% non-susceptible rates to imipenem and meropenem, respectively. Almost all the CR-EC isolates showed resistances to cephalosporins, especially to CRO, CAZ and FEP. Although NDM does not normally show activity against the monobactams such as aztreonam, CR-EC isolates showed high resistances to aztreonam, about 88.9%, probably due to the high prevalence of *bla*~CTX--M~ among these isolates ([Table 1](#T1){ref-type="table"}). Moreover, over half of the CR-EC strains exhibited resistance to aminoglycoside and gentamycin. However, these CR-EC isolates were mostly susceptible to tigecycline and colistin. Compared with carbapenemase-negative isolates, our research revealed that a significantly greater proportion of carbapenemase-positive *E. coli* isolates were resistant to most antibiotics, including ETP, imipenem, meropenem, FEP, CIP, and LEV. Notably, 86.2% (94/109) of the CR-EC isolates were identified to be multi-drug resistant (MDR) as they were resistant to three or more classes of antimicrobial agents.

###### 

Antimicrobial susceptibility of CR-EC isolates with or without carbapenemases.

  Antimicrobial agents   Total (*N* = 109)   Carbapenemase positive (*N* = 50)   Carbapenemase negative (*N* = 59)   *P* value                                                    
  ---------------------- ------------------- ----------------------------------- ----------------------------------- ----------- ----------- ------------ ------ ----- ---------- ----------
  Ertapenem              106 (97.3)          50 (100.0)                          32                                  256         2--512      56 (94.9)    4      64    1--512     \< 0.001
  Imipenem               63 (57.8)           50 (100.0)                          32                                  128         4--512      13 (22.0)    1      8     0.25--32   \< 0.001
  Meropenem              61 (55.9)           48 (96.0)                           8                                   54          0.25--256   13 (22.0)    1      8     0.25--8    \< 0.001
  Ceftriaxone            109 (100.0)         50 (100.0)                          128                                 512         64--512     59 (100.0)   64     128   16--512    --
  Ceftazidime            102 (93.6)          50 (100.0)                          128                                 512         64--512     52 (88.2)    64     128   1--256     \< 0.001
  Cefepime               101 (92.7)          49 (98.0)                           128                                 512         8--512      52 (88.1)    64     128   1--256     \< 0.001
  Aztreonam              97 (88.9)           48 (96.0)                           128                                 512         8--512      49 (83.0)    64     256   2--256     \< 0.001
  Ciprofloxacin          85 (77.9)           41 (82.0)                           16                                  32          0.25--32    44 (74.6)    4      8     0.25--16   \< 0.001
  Levofloxacin           76 (69.7)           37 (74.0)                           16                                  64          0.25--64    39 (66.1)    8      8     0.25--32   \< 0.001
  Gentamycin             70 (64.2)           34 (68.0)                           32                                  128         1--512      36 (61.0)    16     16    1--32      0.02
  Tobramycin             51 (46.8)           24 (48.0)                           8                                   128         1--512      27 (45.8)    8      16    1--32      0.735
  Colistin               22 (20.2)           12 (24.0)                           1                                   4           1--8        10 (16.9)    1      8     1--8       0.988
  Tigecycline            0 (0.00)            0 (0.00)                            1                                   4           0.25--4     0 (0.0)      0.25   1     0.25--2    --

Data are number resistant (% of resistance rates).

P

-value for comparisons of the resistance rates of carbapenemase-positive and carbapenemase-negative groups. Bold face indicates values that are significant (

P

\< 0.05). R, resistance.

Genotypic Distribution of the CR-EC Isolates {#S3.SS2}
--------------------------------------------

Among the 109 CR-EC isolates, 50 (45.9%) strains were demonstrated to be carbapenemase-producers, and most notably, all the 50 strains were positive for NDM, among which 41 (82.0%) of them were NDM-5-positive, 8 (16.0%) were NDM-1-positive, and 1 (2.0%) was NDM-9-positive. Notably, there was one isolate co-harboring *bla*~NDM--5~ and *bla*~KPC--2~. In addition to the production of carbapenemases, 76.2% (83/109) of the isolates were demonstrated to be ESBLs-positive, and *bla*~CTX--M~ was the most prevalent ESBLs gene in the CR-EC isolates, with *bla*~CTX--M--1~ being the most prevalent (42.2%, 46/109) subtype, followed by *bla*~CTX--M--9~ (22.9%, 25/109) and *bla*~CTX--M--15~ (21.1%, 23/109) subtypes. Notably, all the 50 NDM-positive isolates were demonstrated to be co-harboring ESBLs. Besides *bla*~CTX--M~, *bla*~TEM~ (exclusively *bla*~TEM--1~) also showed a high prevalence (32.1%, 35/109). However, no AmpC positive strains were identified. In addition, loss of expression of OmpC and OmpF were not common in CR-EC isolates, only accounting for 24.8% (27/109) and 19.3% (21/109) of these isolates. Notably, 45.9% (50/109) of the isolates were demonstrated to be co-harboring carbapenemases and ESBLs; and 11.0% (12/109) of the isolates co-produced carbapenemases and ESBLs with OMPs loss ([Table 2](#T2){ref-type="table"}). Most of the patients carrying NDM-producers were from ICU (28%, 14/50), the hepatological surgery department (12%, 6/50), and the gastrointestinal surgery department (8%, 4/50). Patients who didn't carry NDM-producers were mostly from the hepatological surgery department (23.7%, 14/59), the urinary surgery department (11.86%, 7/59), and the gastrointestinal surgery department (10.16%, 6/59). It was interesting that isolates carrying the *bla*~NDM--5~ gene were mostly from sputum (10/50, 20.0%), urine (8/50, 16.0%), and blood (6/50, 12.0%), nevertheless, NDM negative isolates were mostly from urine (20/59, 33.8%), bile (7/59, 11.8%), and sputum (7/59, 11.8%).

###### 

Presence of antibiotic resistance genes in clinical carbapenemase-positive and carbapenemase-negative CR-EC isolates.

  Carbapenem resistance mechanisms      Total (109)   Carbapenemase positive (50)   Carbapenemase negative (59)   
  ------------------------------------- ------------- ----------------------------- ----------------------------- ------------
  Carbapenemase type(s)                 50(45.9%)                                                                 
  NDM- positive                         NDM-1         8(7.3%)                       8(16.0%)                      NA
                                        NDM-5         41(37.6%)                     41(82.0%)                     
                                        NDM-9         1(0.9%)                       1(2.0%)                       
  KPC- positive                         KPC-2         1(0.9%)                       1(2.0%)                       NA
  NDM-5, KPC-2                                        1(0.9%)                       1(2.0%)                       NA
  ESBL type(s)                                        83(76.2%)                                                   
  CTXM- positive                        CTXM-1        46(42.2%)                     24(48.0%)                     22 (37.3%)
                                        CTXM-9        25(22.9%)                     16(32.0%)                     9 (15.3%)
                                        CTXM-15       23(21.1%)                     16(32.0%)                     7 (11.9%)
  TEM- positive                         TEM-1         35(32.1%)                     29(58.0%)                     6 (10.2%)
  OXA-1-positive                        OXA-1         23(21.1%)                     8(16.0%)                      15 (25.4%)
  OMPs loss                                           32(29.4%)                                                   
  OMPs                                  OmpC          27(24.8%)                     12(24.0%)                     15 (25.4%)
                                        OmpF          21(19.3%)                     11(22.0%)                     10 (16.9%)
                                        OmpC, OmpF    16(14.7%)                     4(8.0%)                       12 (20.3%)
  Carbapenemase, ESBL type              50(45.9%)     50(100.0%)                    NA                            
  Carbapenemase, ESBL type, OMPs loss   12(11.0%)     12(24.0%)                     NA                            
  Carbapenemase, OMPs loss              12(11.0%)     12(24.0%)                     NA                            
  ESBL type, OMPs loss                  27(24.8%)     12(24.0%)                     15 (25.4%)                    

NA, not applicable.

Characteristics of the Isolated CR-EC Strains Carrying *bla*~NDM--5~ {#S3.SS3}
--------------------------------------------------------------------

The *bla*~NDM--5~-carrying CR-EC isolates were found to be more resistant to carbapenems than CR-EC isolates carrying other *bla*~NDM~ subtypes. While PCR assays demonstrated that *bla*~NDM--5~ was successfully transferred by both conjugation and transformation experiments in all the CR-EC isolates carrying the *bla*~NDM--5~ gene, multiple attempts to co-transfer or co-conjugate *bla*~KPC--2~ and *bla*~NDM--5~ failed, and no transconjugants or transformants co-harboring *bla*~KPC--2~ and *bla*~NDM--5~ were detected. Notably, all of the transconjugants and transformants acquired multi-drug resistance phenotypes similar to those of the donors except for reduced MICs to carbapenems and cephalosporins, and still remained susceptible to colistin and tigecycline. According to the plasmid replicon typing results, plasmid types of the transconjugants and transformants harboring *bla*~NDM~ were IncF (33/50, 66.0%), IncX (11/50, 22.0%), IncH (3/50, 6.0%), and IncA/C (1/50, 2.0%). For chromosomal characteristics, the most prevalent sequence types (STs) was ST167 (12/50, 24.0%), followed by ST410 (5/50, 10.0%) and ST354 (3/50, 6.0%). Some rare ST types, including ST973 and ST746, were also witnessed, only accounting for 4.0% of the isolates, respectively. Notably, 16.0% of the CR-EC isolates still remain unknown ST types. PFGE was performed on all the 41 *bla*~NDM--5~-positive isolates, and all but 2 (*E. coli*-34 and *E. coli*-1002) of these strains showed a different PFGE band pattern ([Table 3](#T3){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}).

###### 

Profiles of plasmids and corresponding average carbapenem MICs in 50 *bla*~NDM~-positive *E. coli* clinical isolates.

  Characteristics                                          NDM-5            NDM-1       NDM-9
  ---------------------- --------------------------------- ---------------- ----------- -------
  Average MICs (μg/ml)   ETP                               84.79            31.75       8
                         IPM                               55.10            31          8
                         MEM                               27.67            8.13        4
  MLST                   ST167 (10)                        ST167 (1)        ST167 (1)   
                         ST410 (5)                         ST361 (1)                    
                         ST354 (3)                         ST4538 (1)                   
                         ST973 (2)                         ST453 (1)                    
                         ST746 (2)                         Unknown ST (4)               
                         Unknown ST (8) Other types (11)                                
  Replicon type          IncF (26)                         IncF (6)         IncF (1)    
                         IncX (9)                          IncX (2)                     
                         IncA/C (1)                                                     
                         IncH (3) UnknownType (2)                                       

ETP, ertapenem; IPM, imipenem; MEM, meropenem.

![Dendrogram analysis and molecular epidemiology of NDM-5 positive *Escherichia coli* isolates. The dendrogram is based on the similarity of PFGE patterns from 41 *bla*~NDM--5~ positive clinical *E. coli* isolates. The right columns illustrate results of source, date, PFGE, MLST, ESBLs, and plasmid types.](fmicb-11-00334-g001){#F1}

Sequence Analysis of Plasmid Containing *bla*~NDM--5~ {#S3.SS4}
-----------------------------------------------------

High throughput sequencing analysis was conducted on *E. coli*-1001, a strain co-harboring *bla*~KPC--2~ and *bla*~NDM--~*~5~* genes. The 139-kb pNDM-5-1001 plasmid was identified to be of the IncF replicon type: containing FIA and FIB replicons, and also co-harboring *bla*~CTX--M15~, *bla*~OXA--1~, aminoglycoside resistance genes \[*aac(6')-I*, *aac(6')-II*\], and tetracycline resistance gene (*tet*). Within the pNDM-5-1001 plasmid, *bla*~NDM--5~ was bracketed by two insertion sequences IS26, containing the ISCR1 element and some other resistance genes ([Figure 2](#F2){ref-type="fig"}). Further sequence alignments based on BLAST revealed that the plasmid sequence showed the most similar nucleotide sequences to those of the following previously reported plasmids: pGUE-NDM (accession number [JQ364967.1](JQ364967.1)) from an *E. coli* strain, pNDM5-020007 (accession number [CP025626.1](CP025626.1)) from an *E. coli* strain, and pNDM-5-IT (GenBank accession No. [MG649062.1](MG649062.1)) from an *E. coli* strain, but less similar to pNDM-BJ01 (GenBank accession No. [JQ001791](JQ001791)) from an *Acinetobacter lwoffii* (*A. lwoffii*) strain, which is the first NDM-expressing plasmid known to have been fully sequenced in China. The identical regions, including the replicon, stabilization elements, toxin-antitoxin systems (*sopA* and *sopB*) and virulence factors (*arcA*, *arcB*, *arc*, and *arcD*), were highly conserved ([Figure 2](#F2){ref-type="fig"}).

![Schematic map of plasmid pNDM-5-1001 and comparative analysis of plasmid pNDM-5-1001 with other three *bla*~NDM--5~-carrying plasmids and pNDM-BJ01. Reference sequences: pNDM-BJ01 from an *Acinetobacter lwoffii* strain (GenBank accession No. [JQ001791](JQ001791)), pNDM-5-IT from an *E. coli* strain (GenBank accession No. [MG649062.1](MG649062)), pGUE_NDM from an *E. coli* strain (GenBank accession number [JQ364967.1](JQ364967.1)), and [pNDM5-020007](pNDM5-020007) from an *E. coli* strain (GenBank accession number [CP025626.1](CP025626.1)).](fmicb-11-00334-g002){#F2}

For genetic environments, 50 NDM-positive isolates were divided into five different types (A to E) based on the analysis of genetic structures, among which type A was the most common (*n* = 25), followed by type E (*n* = 9), type B (*n* = 8), type D (*n* = 5), and type C (*n* = 3). For type A, the flanking genetic structure of the *bla*~NDM--5~ gene was composed of an IS*3000* and incomplete IS*Aba125* interrupted by IS5 located upstream, and the genes *ble*~MBL~ (bleomycin resistance gene), *trpF* (phosphoribosylanthranilate isomerase), *tat* (DsbC superfamily protein), *dct*, *IS26*, and *umD*. Type B had a complete deletion of IS*3000* and IS*Aba125;* type C and type D only had *IS3000* and *IS26*, respectively. Type E, another prevalent type which was different from type A, harbored another insertion sequence (ISCR1), followed by the *sul* gene (sulfonamide-resistant dihydropteroate synthase), the *QacED1* (quaternary ammonium compound resistance protein), the *AadA2* (aminoglycoside nucleotidyltransferase), the *dfrA12* (dihydrofolate reductase), and the *IntI1* (class 1 integron integrase) genes downstream, the *MphR* (Macrolide 2′-phosphotransferase), the *Mrx* (major facilitator family protein transporter), and the *Mph* \[Mph(A) family macrolide 2′-phosphotransferase\] upstream ([Figure 3](#F3){ref-type="fig"}). As for the *bla*~KPC--2~ gene, we did not extract a KPC-2-expressing plasmid in this isolate. Moreover, multiple transformation and transconjugation experiments by the *bla*~KPC--2~-carrying bacteria failed. Thus, we speculated that the *bla*~KPC--2~ gene was most likely to be located on the chromosome.

![Comparison of the genetic elements surrounding the *bla*~NDM--5~ gene identified in this study with the other similar sequences. Reference sequences: pNDM-BJ01 (GenBank accession No. [JQ001791](JQ001791)) from an *A. lwoffii* strain, p744T-NDM5 (GenBank accession No. [MF547511.1](MF547511.1)) from an *E. coli* strain, and pNDM-5-IT (GenBank accession No. [MG649062.1](MG649062.1)) from an *E. coli* strain.](fmicb-11-00334-g003){#F3}

Discussion {#S4}
==========

In the present study, 37.61% (41/109) of the CR-EC isolates were identified to be NDM-5-producers, with most isolates carrying the IncF-type plasmids and ST167 being the most common ST type. Moreover, a clinical carbapenem-resistant *E. coli* isolate co-harboring *bla*~KPC--2~ and *bla*~NDM--5~ was reported for the first time, with the characterizations of its genetic environment. Our findings revealed a new potential threat of NDM-5-postive CR-EC in mainland China, emphasizing an urgent need to control their further spread.

Some conclusions of this study were noteworthy.

First, our results revealed that the main carbapenem resistance mechanism of the CR-EC isolates collected in our hospital could be attributed to the productions of carbapenemases and ESBL/AmpC enzymes combined with porin deficiencies. Notably, while NDM-1 subtype was reported to be the most prevalent from previous studies in China ([@B21]; [@B17]), NDM-5 was observed to be prevalent among the CR-EC isolates. Most importantly, our study revealed that the most prevalent epidemic incompatibility type of the *bla*~NDM--5~-carrying plasmids in our region is IncF (such as IncFIA, IncFIB, and IncFII), which was substantially different from those reported by the other NDM-5 studies (IncA/C and IncX3-type) ([@B11]; [@B16]), indicating that a new molecular epidemiological CR-EC will be prevalent in China. In addition, a more recent study from eastern China have shown several *bla*~NDM--5~-positive *E. coli* infections linked to ST167-type CR-EC ([@B20]), which was also located on the IncX3 plasmid. Moreover, comparisions of the susceptibility results revealed that the *E. coli* isolates carrying the *bla*~NDM--5~ gene were more resistant than those with *bla*~NDM--1~ or *bla*~NDM--9~.

Second, we reported for the first time a clinical *E. coli* strain co-producing NDM-5 and KPC-2, which was isolated from sputum of a patient with respiratory infection. This isolate showed high-level resistances to many antibiotics, but remained susceptible to both tigecycline and colistin. Moreover, while the *bla*~NDM--5~ gene was demonstrated to be located on separate IncF-type plasmids, the *bla*~KPC--2~ gene failed to transfer into a recipient isolate with repeated experiments. To further determine the location of the *bla*~KPC--2~ gene, we performed high-throughput plasmid sequencing and did not find the *bla*~KPC--2~ gene in plasmid sequencing results, indicating that the *bla*~KPC--2~ gene might be located on the chromosome.

Third, we found five different types of *bla*~NDM~ gene environments. Of the greatest interest was that all the NDM-producers all carried the highly conserved regions (*bla*~NDM~-*ble*~MBL~-*trpF*-*tat*) surrounding the *bla*~NDM~ gene, suggesting that these four genes were important elements that produced resistances and were not lost during NDM-5 transmission. To the best of our knowledge, this is also the first report of Type C in China, which showed a similar genetic context to pNDM-5-IT from Italy. However, none of these patients in our study had a history of traveling abroad. As previous researches have demonstrated that the rolling circle replication of *ISCR1* element could produce the upstream adjacent antibiotic resistance genes, which could be rescued through recombination between homologous fragments ([@B15]; [@B5]), we speculated that the *ISCR1* element in type C could be an important gene assisting *bla*~NDM~ spread via rolling circle transposition.

Conclusion {#S5}
==========

In summary, the present study revealed a new emergence of NDM-5-producing CR-EC in a teaching hospital in Chongqing, China, described the first report of a *bla*~KPC--2~ and *bla*~NDM--5~-coharboring *E. coli* isolate, and indicated for the first time that the IncF-type plasmids may contribute to the prevalence of *bla*~NDM--5~, highlighting an urgent need to develop effective measures to prevent and control the further spread of *bla*~NDM--5~ in China.
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